Antihelminthics Market

• April 2019:The WHO prequalified VERMOX (Mebendazole) CHEWABLE, a new medicine from Janssen Pharmaceuticals Inc., for intestinal worms. Following the WHO prequalification, this product is likely to be accessible to young children under the age of one, particularly in nations with a high burden.

• September 2018:Albendazole 200 mg tablet's Abbreviated New Drug Application (ANDA) was finally approved, according to Cipla.

In the report, The Antihelminthics Market has been segmented by Type, Distribution Channel, Applications, End User and Geography.

Antihelminthics Market, Segmentation by Type

The Antihelminthics Market has been segmented by Type into Hormone drugs, Abamectin, Salicylanilides, Praziquantel and Others.

Hormone Drugs
Hormone-based antihelminthics work by disrupting the endocrine pathways of parasitic worms, rendering them incapable of survival or reproduction. This segment contributes approximately 19% to the market. These drugs are often used for targeted parasite control in both humans and animals.

Abamectin
Abamectin, derived from Streptomyces avermitilis, is highly effective against roundworms and ectoparasites. Known for its strong antiparasitic properties and low toxicity, it holds nearly 24% of the market. Its widespread use in veterinary and agricultural applications drives segment growth.

Salicylanilides
Salicylanilides are commonly used to treat liver flukes and blood-feeding parasites, particularly in livestock. They function by disrupting the mitochondrial function of helminths. This segment represents about 17% of the market and is essential in animal health management.

Praziquantel
Praziquantel is a first-line treatment for schistosomiasis and tapeworm infections, especially in developing countries. It contributes nearly 28% of the market, owing to its broad-spectrum efficacy, oral bioavailability, and support from global public health initiatives.

Others
The 'Others' segment includes diverse compounds such as benzimidazoles, levamisole, and piperazine used across various helminth infections. This category makes up roughly 12% of the market and continues to expand with increasing focus on mass deworming programs and veterinary applications.

Antihelminthics Market, Segmentation by Distribution Channel

The Antihelminthics Market has been segmented by Distribution Channel into Hospitals, Pharmacies, Online Pharmacies, and Veterinary Clinics

Hospitals
Hospitals account for approximately 34% of the antihelminthics market, driven by the treatment of severe helminthic infections that require inpatient care and intravenous drug administration. Hospitals also play a key role in managing co-infections in immunocompromised patients, contributing to higher drug utilization.

Pharmacies
Retail pharmacies contribute nearly 28% of the market, primarily catering to patients with prescription-based and over-the-counter antihelminthics. Their broad accessibility and ability to provide immediate medication make them a preferred distribution channel in both urban and semi-urban areas.

Online Pharmacies
Online pharmacies are rapidly gaining market share, currently accounting for around 18%. Growing consumer preference for convenient access, home delivery, and price transparency is fueling this segment, especially for OTC medications used in routine deworming treatments.

Veterinary Clinics
Veterinary clinics serve as a critical distribution channel for antihelminthics in animal healthcare and represent about 20% of the overall market. These facilities offer diagnosis-driven treatment for livestock and companion animals and play an important role in the control of zoonotic helminths.

Antihelminthics Market, Segmentation by Applications

The Antihelminthics Market has been segmented by Applications into Schistosomiasis, Fasciolasis, Filariasis, Angiostrongylosis, Ascariasis, Giardiasis and Others.

Schistosomiasis
Schistosomiasis is a significant parasitic infection prevalent in tropical regions, especially sub-Saharan Africa. This segment accounts for around 28% of the market, largely driven by the use of praziquantel in mass drug administration (MDA) programs supported by WHO and global health agencies.

Fasciolasis
Fasciolasis is caused by liver flukes and is commonly found in both humans and livestock. It holds approximately 14% of the antihelminthics market. Triclabendazole is the primary drug used, with demand rising due to increasing cases in agricultural regions.

Filariasis
Filariasis, including lymphatic filariasis, affects millions globally and contributes nearly 18% to the market. Treatment involves ivermectin, albendazole, and diethylcarbamazine, supported by large-scale elimination campaigns in endemic countries.

Angiostrongylosis
Angiostrongylosis is a less common but potentially severe parasitic infection caused by Angiostrongylus cantonensis. It represents around 6% of the market. Diagnosis and treatment awareness are improving in regions where the parasite is emerging due to climate change and globalization.

Ascariasis
Ascariasis, caused by the intestinal roundworm Ascaris lumbricoides, is one of the most common helminthic infections globally. It makes up nearly 16% of the market and is widely addressed through mass deworming programs using drugs like mebendazole and albendazole.

Giardiasis
Giardiasis, although caused by a protozoan, is often included in antihelminthic treatment categories due to its similar gastrointestinal symptoms. It contributes approximately 11% to the market. Metronidazole and tinidazole are the primary treatments used in both endemic and non-endemic regions.

Others
The 'Others' segment includes treatments for helminth infections such as taeniasis, strongyloidiasis, and trichuriasis. Collectively, these make up around 7% of the market. Increasing global surveillance and access to combination therapies are expected to expand this category.

Antihelminthics Market, Segmentation by End User

The Antihelminthics Market has been segmented by End User into Hospitals, Clinics and Others.

Hospitals
Hospitals lead the antihelminthics market with an estimated share of 46%, owing to the treatment of severe helminthic infections and inpatient care requirements. These facilities are crucial for administering IV formulations and managing patients with co-infections or complications related to parasitic diseases.

Clinics
Clinics contribute approximately 32% to the market and serve as primary centers for outpatient diagnosis and treatment of helminthic infections. They are particularly important in urban and semi-urban areas, offering access to oral antihelminthics and routine deworming consultations.

Others
The 'Others' segment, which includes pharmacies, community health centers, and home-based care settings, accounts for around 22% of the market. The rising adoption of OTC antihelminthic drugs and the growing reach of mass deworming campaigns are fueling growth in this segment.

Antihelminthics Market, Segmentation by Geography

The Antihelminthics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Antihelminthics Market Share (%), by Geographical Region

North America
North America holds approximately 27% of the antihelminthics market, driven by increased awareness of travel-related parasitic infections and the rise of zoonotic helminths in both humans and animals. Strong veterinary healthcare systems and advanced diagnostic infrastructure support steady growth in this region.

Europe
Europe accounts for nearly 23% of the market, largely due to improved access to prescription deworming agents and animal healthcare initiatives. Countries like Germany and the UK have strong surveillance programs and are leading in veterinary antihelminthic consumption.

Asia Pacific
Asia Pacific dominates the global market with a share of around 31%, fueled by a high burden of soil-transmitted helminths, government-led deworming programs, and a large rural population. India, China, and Southeast Asia are key contributors to the region’s significant volume growth.

Middle East and Africa
Middle East and Africa contribute roughly 12% to the market. The high prevalence of parasitic infections, limited access to clean water, and expanding public health campaigns aimed at mass deworming are driving demand in this region, particularly in sub-Saharan Africa.

Latin America
Latin America holds about 7% of the global market. Countries like Brazil and Peru face a moderate burden of helminthic diseases, with increasing adoption of anti-parasitic drugs through both public health systems and private healthcare facilities.

This report provides an in depth analysis of various factors that impact the dynamics of Global Antihelminthics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers:

• Expansion of Healthcare Access in Developing Regions
• Rising Demand for Veterinary Antiparasitic Treatments
• Government Support and Funding for Control Programs

• Growing Awareness about Neglected Tropical Diseases: The global antihelminthics market is witnessing a surge in awareness about neglected tropical diseases (NTDs), driving significant growth. These diseases, predominantly affecting populations in low-income regions of Asia, Africa, and Latin America, are characterized by high morbidity and mortality rates. Increasing efforts by governments, non-governmental organizations (NGOs), and international health bodies to raise awareness about NTDs such as soil-transmitted helminthiasis, schistosomiasis, and lymphatic filariasis have propelled the demand for antihelminthic treatments. The emphasis on preventive chemotherapy programs and mass drug administration campaigns has further bolstered market growth, aiming to reduce the burden of these diseases on vulnerable populations.

  Pharmaceutical companies are increasingly focusing on developing affordable and accessible antihelminthic drugs tailored to the specific needs of endemic regions. Collaborations between governments, NGOs, and healthcare providers are crucial in expanding treatment coverage and ensuring sustainability in disease control efforts. As awareness continues to grow, particularly through educational initiatives and community engagement, the global antihelminthics market is poised to see continued expansion in addressing neglected tropical diseases effectively.

Restraints:

• Drug Resistance in Helminths
• Limited Access to Healthcare in Remote Areas
• High Cost of Antihelminthic Treatments

• Adverse Effects and Safety Concerns: The global antihelminthics market faces challenges related to adverse effects and safety concerns, which impact its growth and adoption. Many antihelminthic drugs, while effective in treating parasitic infections, can cause a range of adverse effects such as nausea, vomiting, abdominal pain, and dizziness. These side effects can lead to patient non-compliance or discontinuation of treatment, particularly in vulnerable populations such as children and pregnant women. Moreover, certain antihelminthic medications have been associated with more serious adverse reactions, including liver toxicity and neurological symptoms, which underscore the importance of careful monitoring and dosage management.

  Safety concerns also extend to drug resistance, where repeated or improper use of antihelminthics can lead to the development of resistant parasites. This poses a significant challenge in regions with endemic parasitic diseases, necessitating ongoing research and development of new treatment options. Regulatory bodies play a crucial role in ensuring the safety and efficacy of antihelminthics through rigorous approval processes and post-market surveillance, aiming to mitigate risks while promoting effective treatment outcomes. Addressing these adverse effects and safety concerns remains pivotal for sustaining growth and enhancing the global antihelminthics market's role in combating parasitic infections worldwide.

Opportunities:

• Development of Novel Antihelminthic Formulations
• Expansion of Screening and Treatment Programs
• Increasing Focus on One Health Approach

• Collaboration for Research and Development: Collaboration for research and development is increasingly vital in the global antihelminthics market to address the complex challenges posed by parasitic infections. Pharmaceutical companies, academic institutions, governments, and non-profit organizations are pooling resources and expertise to accelerate the discovery and development of new antihelminthic treatments. These collaborations leverage diverse perspectives and capabilities to innovate in drug discovery, formulation, and delivery systems tailored to specific parasitic diseases prevalent in different regions.

  Partnerships facilitate the sharing of scientific knowledge, data, and clinical trial resources, expediting the evaluation of potential antihelminthic candidates. Initiatives like public-private partnerships and consortia dedicated to neglected tropical diseases ensure that research efforts are focused on the most pressing global health priorities. By fostering collaboration across borders and disciplines, the global antihelminthics market can effectively tackle emerging challenges such as drug resistance and safety concerns while striving to provide affordable and accessible treatments to underserved populations.